Helsinn Healthcare

Closed portfolio with a later-stage archive tilt

According to ClinicalTrials.gov-derived indexes, Helsinn Healthcare sits in the top decile of US sponsors by registered trial count (#801 of 15,742 sponsors by registered trial count).

18 total trials none currently recruiting 15 completed later-stage tilt top decile by trial count

Helsinn Healthcare: 18 sponsored US clinical trials, none currently recruiting.

Helsinn Healthcare sponsors 18 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 15 completed. 11 of these trials are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Cachexia; Cancer, with 1 trials.

Top-decile sponsor footprint

Helsinn Healthcare ranks in the top decile of sponsors by registered trial count (#801 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 48/100

15 of 18 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (83.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

18 total, page 1 of 1

COMPLETED Phase 3

A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT03743064

COMPLETED Phase 3

A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT03743051

COMPLETED Phase 3

A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast Cancer

NCT03403712

COMPLETED Phase 2

PK/PD Study of Netupitant and Palonosetron in Pediatric Patients for Prevention of Chemotherapy-induced Nausea and Vomiting

NCT03204279

TERMINATED Phase 3

An Efficacy and Safety Study Of Pracinostat In Combination With Azacitidine In Adults With Acute Myeloid Leukemia

NCT03151408

TERMINATED Phase 2

A Safety and Efficacy Study of Pracinostat and Azacitidine in Patients With High Risk Myelodysplastic Syndromes

NCT03151304

COMPLETED Phase 3

A Safety Study of Intravenous Pro-Netupitant and Palonosetron Combination for the Prevention of Nausea and Vomiting

NCT02517021

COMPLETED Phase 1

Evaluate the Effects of Itraconazole and Ciprofloxacin on Single-Dose PK of Pracinostat in Healthy Nonsmoking Subjects

NCT02118909

COMPLETED Early Phase 1

Study to Evaluate the Food Effect of Single-dose Bioavailability of Pracinostat in Healthy Adult Subjects

NCT02058784

COMPLETED Phase 2

Safety and Efficacy Study of Pracinostat With Azacitadine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

NCT01912274

COMPLETED Phase 2

Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA

NCT01993641

COMPLETED Phase 2

Phase 2 Study of Pracinostat With Azacitidine in Patients With Previously Untreated Myelodysplastic Syndrome

NCT01873703

COMPLETED Phase 3

Efficacy and Safety of Palonosetron Intravenous in Prevention of Chemotherapy Induced Nausea and Vomiting in Pediatric Patients

NCT01442376

COMPLETED Phase 3

A Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting

NCT01376297

COMPLETED Phase 3

An Efficacy and Safety Study of Oral and Intravenous Palonosetron for the Prevention of Nausea and Vomiting

NCT01363479

COMPLETED Phase 3

Safety and Efficacy of Palonosetron IV to Prevent Postoperative Nausea and Vomiting in Pediatric Patients

NCT01395901

COMPLETED Phase 3

An Efficacy and Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting

NCT01339260

TERMINATED Phase 3

XL119 Versus 5-Fluorouracil (5-FU) Plus Leucovorin (LV) in Subjects With Advanced Biliary Tumors

NCT00090025

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 5
Phase 3 11

How the Helsinn Healthcare archive is shaped

18 indexed studies, none listed as recruiting (0% open); 15 completed (83%).

Phase mix: 11 late (III/IV) vs 7 early (I/II) (later-stage heavy).

Top condition: Cachexia; Cancer (1 trial), 1 other listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Helsinn Healthcare: archived-pipeline peers nationwide

Peers matched on 18 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Helsinn Healthcare sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05101520 0%10%20%30%40% Total trials Recruiting share Helsinn HealthcareADC Therapeutics S.A.Akros PharmaAO Clinical Investigation and Publishing DocumentationAO Innovation Translation Center10xBio22nd Century Group23andMe3-C Institute for Social Development
Helsinn Healthcare sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Helsinn Healthcare sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 18 archived trials

Sponsors with similar archive density (± trial count)

What to do with this Helsinn Healthcare page

18 registered trials is a research-attention snapshot, not an endorsement of Helsinn Healthcare or any single study.

  • None of Helsinn Healthcare's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Cachexia; Cancer is the condition Helsinn Healthcare studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Cachexia; Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Helsinn Healthcare pipeline card: 18 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.